Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to
arise as the disease progresses. A growing body of evidence suggests that pathological …

Gene transfer has long been a compelling yet elusive therapeutic modality. First mainly
considered for rare inherited disorders, gene therapy may open treatment opportunities for …

The growth factor brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-
related kinase receptor type B (TRKB) are actively produced and trafficked in multiple …

Improvements in the gene transfer vectors used in therapeutic trials have led to substantial
clinical successes in patients with serious genetic conditions, such as immunodeficiency …

Nanotechnology has brought a variety of new possibilities into biological discovery and
clinical practice. In particular, nano-scaled carriers have revolutionalized drug delivery …

Convection-enhanced delivery (CED) is a bulk flow–driven process. Its properties permit
direct, homogeneous, targeted perfusion of CNS regions with putative therapeutics while …

The concept of repairing the brain with growth factors has been pursued for many years in a
variety of neurodegenerative diseases including primarily Parkinson's disease (PD) using …

Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates
remain poor despite decades of clinical trials of conventional and novel, biologically …

Convection-enhanced delivery (CED) is a method used to increase transport of therapeutics
in and around brain tumors. CED works through locally applying a pressure differential to …

Over the past decade, nine gene therapy clinical trials for Parkinson's disease (PD) have
been initiated and completed. Starting with considerable optimism at the initiation of each …